阿立哌唑联合奥拉西坦对精神分裂症患者认知功能的影响

目的观察阿立哌唑与奥拉西坦联合治疗对精神分裂症患者认知功能的影响,为精神分裂症认知损伤的治疗提供临床证据。方法采用随机数字表法将98例符合《国际疾病分类(第10版)》(ICD-10)诊断标准的精神分裂症患者分为研究组(阿立哌唑10~30 mg/d联合奥拉西坦1 600~2 400 mg/d)和对照组(阿立哌唑10~30 mg/d)各49例,进行为期8周的随机对照研究。在治疗开始前与治疗结束时(第8周末)采用阳性和阴性症状量表(PANSS)进行临床疗效评定,采用MATRICS共识认知成套测验(MCCB)评定认知功能。结果治疗8周末,两组MCCB和PANSS评分较治疗前均有改善,差异均有统计学意义(P均0.05);研究组在语义流畅性、连线测验、符号编码、持续操作、情绪管理五项指标的评分低于对照组,差异均有统计学意义(P均0.05)。结论阿立哌唑联合奥拉西坦与单用阿立哌唑对精神分裂症疗效相当,但前者对精神分裂症认知功能损害的疗效优于单用阿立哌唑。

Efficacy of aripiprazole combined with oxiracetam on cognitive in schizophrenia patients

Objective To evaluate the efficacy of aripiprazole combined with oxiracetam on cognitive function in patients with schizophrenia. Methods A total of 98 schizophrenics based on ICD - 10 were randomly divided into study group treated with aripiprazole combined with oxiracetam and control group treated with aripiprazole monotherapy for 8 weeks. Assessments were conducted with the Positive and Negative Syndrome Scale( PANSS),MATRICS Consensus Cognitive Battery( MCCB)before and after the treatment. Results At the 8th weekend,scores of MCCB and PANSS were improved significantly compared with those at baseline(P <0. 05). Total score of the semantic fluency,trail making test,signal coding,continuous performance test,managing emotions of MCCB in study group were significantly lower than those in control group(P < 0. 05). Conclusion Aripiprazole combined with oxiracetam could perform better than oxiracetam monotherapy on improving cognitive function in schizophrenic patients,accompanying with comparative effects in treating schizophrenia.